# EDGAR Filing Document

**Accession Number:** 0001944285
**File Stem:** 0000894189-26-001074
**Filing Date:** 2026-1
**Character Count:** 26521
**Document Hash:** 4c4ea14d8a54e54c39a1ec5035f8db17
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000894189-26-001074.hdr.sgml**: 20260121

**ACCESSION NUMBER**: 0000894189-26-001074

**CONFORMED SUBMISSION TYPE**: NPORT-P

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20251130

**FILED AS OF DATE**: 20260121

**DATE AS OF CHANGE**: 20260121

**PERIOD START**: 20260228

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Tema ETF Trust
- **CENTRAL INDEX KEY:** 0001944285

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** NPORT-P
- **SEC ACT:** 1940 Act
- **SEC FILE NUMBER:** 811-23823
- **FILM NUMBER:** 26548814

**BUSINESS ADDRESS:**
- **STREET 1:** 1919 M STREET, N.W., SUITE 700
- **CITY:** WASHINGTON
- **STATE:** DC
- **ZIP:** 20036
- **BUSINESS PHONE:** 3024994928 EXT. 801

**MAIL ADDRESS:**
- **STREET 1:** 1919 M STREET, N.W., SUITE 700
- **CITY:** WASHINGTON
- **STATE:** DC
- **ZIP:** 20036

## Series and Classes Contracts Data

### Tema Heart & Health ETF (Series ID: S000081541)

| Class ID   | Class Name              | Ticker Symbol   |
|:---|:---|:---|
| C000244455 | Tema Heart & Health ETF | HRTS            |

## Nport-Ex

---

| | | |
|:---|:---|:---|
| **Tema Heart & Health ETF** | **Tema Heart & Health ETF** | **Tema Heart & Health ETF** |
| **Schedule of Investments** | **Schedule of Investments** | **Schedule of Investments** |
| **November 30, 2025 (Unaudited)** | **November 30, 2025 (Unaudited)** | **November 30, 2025 (Unaudited)** |
| **COMMON STOCKS - 99.2%** | **Shares** | **Value**  |
| **Biotechnology - 34.4% <sup>(a)</sup>** | **Biotechnology - 34.4% <sup>(a)</sup>** | |
| AbbVie, Inc. | 6769 | $1541301 |
| Alnylam Pharmaceuticals, Inc. <sup>(b)</sup> | 2019 | 911033 |
| Amgen, Inc. | 3239 | 1118945 |
| Arrowhead Pharmaceuticals, Inc. <sup>(b)</sup> | 24089 | 1269490 |
| Ascendis Pharma AS - ADR <sup>(b)</sup> | 2569 | 545476 |
| Bridgebio Pharma, Inc. <sup>(b)</sup> | 15436 | 1111546 |
| Cytokinetics, Inc. <sup>(b)</sup> | 14950 | 1018544 |
| Gilead Sciences, Inc. | 15449 | 1944102 |
| Insmed, Inc. <sup>(b)</sup> | 3959 | 822562 |
| Intellia Therapeutics, Inc. <sup>(b)</sup> | 13524 | 121581 |
| Ionis Pharmaceuticals, Inc. <sup>(b)</sup> | 11318 | 936338 |
| Madrigal Pharmaceuticals, Inc. <sup>(b)</sup> | 1491 | 890097 |
| Mineralys Therapeutics, Inc. <sup>(b)</sup> | 6135 | 264541 |
| Neurocrine Biosciences, Inc. <sup>(b)</sup> | 3372 | 513084 |
| Regeneron Pharmaceuticals, Inc. | 1618 | 1262347 |
| Revolution Medicines, Inc. <sup>(b)</sup> | 13975 | 1086696 |
| Scholar Rock Holding Corp. <sup>(b)</sup> | 12243 | 539427 |
| uniQure NV <sup>(b)</sup> | 6455 | 177577 |
| Vertex Pharmaceuticals, Inc. <sup>(b)</sup> | 3154 | 1367606 |
| Viking Therapeutics, Inc. <sup>(b)</sup> | 9221 | 339425 |
| Zealand Pharma AS <sup>(b)</sup> | 5153 | 413441 |
|  |  | 18195159 |
| **Health Care Equipment & Supplies - 16.8%** | **Health Care Equipment & Supplies - 16.8%** |  |
| Abbott Laboratories | 15393 | 1984157 |
| Boston Scientific Corp. <sup>(b)</sup> | 17053 | 1732244 |
| Dexcom, Inc. <sup>(b)</sup> | 7334 | 465489 |
| Edwards Lifesciences Corp. <sup>(b)</sup> | 9702 | 840872 |
| Insulet Corp. <sup>(b)</sup> | 2246 | 734869 |
| Intuitive Surgical, Inc. <sup>(b)</sup> | 1550 | 888894 |
| Masimo Corp. <sup>(b)</sup> | 4118 | 586527 |
| Medtronic PLC | 15434 | 1625663 |
|  |  | 8858715 |
| **Health Care Providers & Services - 6.0%** | **Health Care Providers & Services - 6.0%** |  |
| McKesson Corp. | 1168 | 1029148 |
| UnitedHealth Group, Inc. | 6577 | 2168897 |
|  |  | 3198045 |
| **Life Sciences Tools & Services - 6.2%** | **Life Sciences Tools & Services - 6.2%** |  |
| Danaher Corp. | 6092 | 1381544 |
| Thermo Fisher Scientific, Inc. | 3186 | 1882384 |
|  |  | 3263928 |
| **Pharmaceuticals - 35.8% <sup>(a)</sup>** | **Pharmaceuticals - 35.8% <sup>(a)</sup>** |  |
| AstraZeneca PLC | 12208 | 2258155 |
| Bristol-Myers Squibb Co. | 18439 | 907199 |
| Chugai Pharmaceutical Co. Ltd. | 16311 | 874417 |
| Crinetics Pharmaceuticals, Inc. <sup>(b)</sup> | 20493 | 933661 |
| Eli Lilly & Co. | 5210 | 5603199 |
| Johnson & Johnson | 7863 | 1627012 |
| Merck & Co., Inc. | 12963 | 1358911 |
| Novartis AG | 11319 | 1472555 |
| Novo Nordisk AS – Class B | 25819 | 1271645 |
| Roche Holding AG - ADR | 48754 | 2331904 |
| Teva Pharmaceutical Industries Ltd. - ADR <sup>(b)</sup> | 9762 | 262500 |
|  |  | 18901158 |
| **TOTAL COMMON STOCKS** (Cost $44,880,238) | **TOTAL COMMON STOCKS** (Cost $44,880,238) | 52417005 |
| **SHORT-TERM INVESTMENTS<br>**  | **SHORT-TERM INVESTMENTS<br>**  | **SHORT-TERM INVESTMENTS<br>**  |
| **MONEY MARKET FUNDS - 0.7%** | **Shares** | **Value**  |
| First American Treasury Obligations Fund - Class X, 3.91% <sup>(c)</sup> | 352581 | 352581 |
| **TOTAL MONEY MARKET FUNDS** (Cost $352,581) | **TOTAL MONEY MARKET FUNDS** (Cost $352,581) | 352581 |
| **TOTAL INVESTMENTS - 99.9% (**Cost $45,232,819**)** | **TOTAL INVESTMENTS - 99.9% (**Cost $45,232,819**)** | 52769586 |
| Other Assets in Excess of Liabilities - 0.1% | Other Assets in Excess of Liabilities - 0.1% | 39742 |
| **TOTAL NET ASSETS - 100.0%** |  | $52809328 |
| Percentages are stated as a percent of net assets. | Percentages are stated as a percent of net assets. |  |
| The Global Industry Classification Standard ("GICS<sup>®</sup>") was developed by and/or is the exclusive property of MSCI, Inc. ("MSCI") and Standard & Poor's Financial Services LLC ("S&P"). GICS<sup>®</sup> is a service mark of MSCI and S&P and has been licensed for use by U.S. Bank Global Fund Services. | The Global Industry Classification Standard ("GICS<sup>®</sup>") was developed by and/or is the exclusive property of MSCI, Inc. ("MSCI") and Standard & Poor's Financial Services LLC ("S&P"). GICS<sup>®</sup> is a service mark of MSCI and S&P and has been licensed for use by U.S. Bank Global Fund Services. | The Global Industry Classification Standard ("GICS<sup>®</sup>") was developed by and/or is the exclusive property of MSCI, Inc. ("MSCI") and Standard & Poor's Financial Services LLC ("S&P"). GICS<sup>®</sup> is a service mark of MSCI and S&P and has been licensed for use by U.S. Bank Global Fund Services. |

---

ADR - American Depositary Receipt <br> PLC - Public Limited Company

(a) To the extent that the Fund invests more heavily in particular industries or sectors of the economy, its performance will be especially sensitive to developments that significantly affect those industries or
 sectors.

(b) Non-income producing security.

(c) The rate shown represents the 7-day annualized yield as of November 30, 2025.

------

 **Tema ETF Trust** 

#### Tema Heart & Health ETF
Notes to Quarterly Schedule of Investments

November 30, 2025 (Unaudited)

#### Investment Valuation
The Fund discloses the fair value of their investments in a hierarchy that distinguishes between: (1) market participant assumptions developed based on market data obtained from sources independent of the Fund's (observable inputs) and (2) the Fund's own assumptions about market participant assumptions developed based on the best information available under the circumstances (unobservable inputs).

The three levels defined by the hierarchy are as follows:

**• Level 1** — Quoted prices in active markets for identical assets that the Fund's have the ability to access.

**• Level 2** — Other significant observable inputs (including quoted prices for similar securities, interest rates, prepayment speeds, credit risk, etc.).

**• Level 3** — Significant unobservable inputs (including the Fund's own assumptions in determining the fair value of investments).

The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities.

The following is a summary of the inputs used to value the Fund's investments as of November 30, 2025:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **<u>Level 1</u>** | **<u>Level 2</u>** | **<u>Level 3</u>** | **<u>Total</u>** |
| **Assets** | | | | |
| **Investments:** | | | | |
|  &nbsp;&nbsp;&nbsp;&nbsp;Common Stocks | $52417005 | $– | $– | $52417005 |
|  &nbsp;&nbsp;&nbsp;&nbsp;Money Market Funds | 352581 | – | – | 352581 |
| **Total Investments** | $52769586 | $– | $– | $52769586 |
| Refer to the Schedule of Investments for further disaggregation of investment categories. | Refer to the Schedule of Investments for further disaggregation of investment categories. | Refer to the Schedule of Investments for further disaggregation of investment categories. | Refer to the Schedule of Investments for further disaggregation of investment categories. | Refer to the Schedule of Investments for further disaggregation of investment categories. |

---

---

| |
|:---|
| **Allocation of Portfolio Holdings by Country as of November 30, 2025** |
| (% of Net Assets) |

---

---

| | | |
|:---|:---|:---|
| United States | $41536253 | 78.7% |
| Switzerland | 3804459 | 7.2 |
| United Kingdom | 2258155 | 4.3 |
| Denmark | 2230562 | 4.2 |
| Ireland | 1625663 | 3.1 |
| Japan | 874417 | 1.6 |
| Israel | 262500 | 0.5 |
| Netherlands | 177577 | 0.3 |
| Other Assets in Excess of Liabilities | 39742 | 0.1 |
|  | $**52809328** | 100.0<br> **%** |

---

---

| |
|:---|
| **Sector Classification as of November 30, 2025** |
| (% of Net Assets) |

---

---

| | | |
|:---|:---|:---|
| Health Care | $52417005 | 99.2% |
| Money Market Funds | 352581 | 0.7 |
| Other Assets in Excess of Liabilities | 39742 | 0.1 |
|  | $**52809328** | 100.0<br> **%** |

---

## Form NPORT-P: Monthly Portfolio Investments Report

### NPORT-P: Part A: General Information

**Item A.1. Information about the Registrant.**

- **a. Name of Registrant:** Tema ETF Trust

- **b. Investment Company Act file number:** 811-23823

- **c. CIK number of Registrant:** 0001944285

- **d. LEI of Registrant:** 549300JKGDXNE2CLUY37

- **e. Address and telephone number of Registrant.**

  - **Street Address 1:** 200 Vesey Street

  - **City:** New York

  - **State:** NY

  - **Foreign country:** US

  - **Zip / Postal Code:** 10281

  - **Telephone number:** 3024994928 EXT 801

**Item A.2. Information about the Series.**

- **a. Name of Series:** Tema Heart & Health ETF

- **b. EDGAR series identifier (if any):** S000081541

- **c. LEI of Series:** 5299002XY0MZ4FAXPP90

**Item A.3. Reporting period.**

- **a. Date of fiscal year-end:** 2026-02-28

- **b. Date as of which information is reported:** 2025-11-30

**Item A.4. Final filing**

Does the Fund anticipate that this will be its final filing on Form N-PORT? **No**

### Fund Information

**Total Assets:** $52840695.58

**Total Liabilities:** $31368.23

**Net Assets:** $52809327.35

**Monthly Return Information**

| Class               | Month 1 Return (%)   | Month 2 Return (%)   | Month 3 Return (%)   |
|:---|:---|:---|:---|
| Class ID C000244455 | 4.26%                | 5.32%                | 10.28%               |

**Monthly Gains & Losses**

| Period   | Net Realized Gain/Loss   | Net Unrealized Appreciation/Depreciation   |
|:---|:---|:---|
| Month 1  | $126359.10               | $2000020.57                                |
| Month 2  | $1196889.86              | $1419965.96                                |
| Month 3  | $698775.79               | $4236581.16                                |

**Designated Index Information**

- **Index Name:** N/A

- **Index Identifier:** N/A

### Schedule of Portfolio Investments

| Name                           | Title                                    | Identifiers                                   | Payoff Profile   | Asset Category   | Issuer Category   | Country   |   Balance | Units   | Value (USD)   | % of Net Assets   | Maturity Date   | Coupon Type   | Annualized Rate (%)   | Restricted?   |   Fair Value Level | Lending Status   |
|:---|:---|:---|:---|:---|:---|:---|---:|:---|:---|:---|:---|:---|:---|:---|---:|:---|
| uniQure NV                     | uniQure NV                               | CUSIP: N/A<br>LEI: 724500RPCTZLFYJZ3S98       | Long             | EC               | CORP              | NL        |      6455 | NS      | $177577.05    | 0.34%             |  |  |  | No            |                  1 | On Loan: No      |
| Boston Scientific Corp         | Boston Scientific Corp                   | CUSIP: 101137107<br>LEI: Y6ZDD9FP4P8JSSJMW954 | Long             | EC               | CORP              | US        |     17053 | NS      | $1732243.74   | 3.28%             |  |  |  | No            |                  1 | On Loan: No      |
| Bristol-Myers Squibb Co        | Bristol-Myers Squibb Co                  | CUSIP: 110122108<br>LEI: HLYYNH7UQUORYSJQCN42 | Long             | EC               | CORP              | US        |     18439 | NS      | $907198.80    | 1.72%             |  |  |  | No            |                  1 | On Loan: No      |
| Dexcom Inc                     | Dexcom Inc                               | CUSIP: 252131107<br>LEI: 549300YSK3QDSFR5EU59 | Long             | EC               | CORP              | US        |      7334 | NS      | $465488.98    | 0.88%             |  |  |  | No            |                  1 | On Loan: No      |
| First American Treasury Obliga | First American Treasury Obligations Fund | CUSIP: 31846V328<br>LEI: 549300UU586IAH2B8H03 | Long             | STIV             | RF                | US        |    352581 | NS      | $352580.52    | 0.67%             |  |  |  | No            |                  1 | On Loan: No      |
| Gilead Sciences Inc            | Gilead Sciences Inc                      | CUSIP: 375558103<br>LEI: 549300WTZWR07K8MNV44 | Long             | EC               | CORP              | US        |     15449 | NS      | $1944102.16   | 3.68%             |  |  |  | No            |                  1 | On Loan: No      |
| Insmed Inc                     | Insmed Inc                               | CUSIP: 457669307<br>LEI: 529900Q55QAG41CCAC11 | Long             | EC               | CORP              | US        |      3959 | NS      | $822561.43    | 1.56%             |  |  |  | No            |                  1 | On Loan: No      |
| Revolution Medicines Inc       | Revolution Medicines Inc                 | CUSIP: 76155X100<br>LEI: 549300JU3X0LBCQ65892 | Long             | EC               | CORP              | US        |     13975 | NS      | $1086696.00   | 2.06%             |  |  |  | No            |                  1 | On Loan: No      |
| Vertex Pharmaceuticals Inc     | Vertex Pharmaceuticals Inc               | CUSIP: 92532F100<br>LEI: 54930015RAQRRZ5ZGJ91 | Long             | EC               | CORP              | US        |      3154 | NS      | $1367605.94   | 2.59%             |  |  |  | No            |                  1 | On Loan: No      |
| AbbVie Inc                     | AbbVie Inc                               | CUSIP: 00287Y109<br>LEI: FR5LCKFTG8054YNNRU85 | Long             | EC               | CORP              | US        |      6769 | NS      | $1541301.30   | 2.92%             |  |  |  | No            |                  1 | On Loan: No      |
| Danaher Corp                   | Danaher Corp                             | CUSIP: 235851102<br>LEI: S4BKK9OTCEWQ3YHPFM11 | Long             | EC               | CORP              | US        |      6092 | NS      | $1381543.76   | 2.62%             |  |  |  | No            |                  1 | On Loan: No      |
| Intuitive Surgical Inc         | Intuitive Surgical Inc                   | CUSIP: 46120E602<br>LEI: 54930052SRG011710797 | Long             | EC               | CORP              | US        |      1550 | NS      | $888894.00    | 1.68%             |  |  |  | No            |                  1 | On Loan: No      |
| Johnson & Johnson              | Johnson & Johnson                        | CUSIP: 478160104<br>LEI: 549300G0CFPGEF6X2043 | Long             | EC               | CORP              | US        |      7863 | NS      | $1627011.96   | 3.08%             |  |  |  | No            |                  1 | On Loan: No      |
| Madrigal Pharmaceuticals Inc   | Madrigal Pharmaceuticals Inc             | CUSIP: 558868105<br>LEI: 549300CHIMT2EUSNJB60 | Long             | EC               | CORP              | US        |      1491 | NS      | $890097.18    | 1.69%             |  |  |  | No            |                  1 | On Loan: No      |
| Teva Pharmaceutical Industries | Teva Pharmaceutical Industries Ltd       | CUSIP: 881624209<br>LEI: 549300BAFGM4RC74ZJ94 | Long             | EC               | CORP              | IL        |      9762 | NS      | $262500.18    | 0.50%             |  |  |  | No            |                  1 | On Loan: No      |
| Thermo Fisher Scientific Inc   | Thermo Fisher Scientific Inc             | CUSIP: 883556102<br>LEI: HCHV7422L5HDJZCRFL38 | Long             | EC               | CORP              | US        |      3186 | NS      | $1882384.38   | 3.56%             |  |  |  | No            |                  1 | On Loan: No      |
| Masimo Corp                    | Masimo Corp                              | CUSIP: 574795100<br>LEI: 549300Q4A8JK0PIYCU29 | Long             | EC               | CORP              | US        |      4118 | NS      | $586526.74    | 1.11%             |  |  |  | No            |                  1 | On Loan: No      |
| Regeneron Pharmaceuticals Inc  | Regeneron Pharmaceuticals Inc            | CUSIP: 75886F107<br>LEI: 549300RCBFWIRX3HYQ56 | Long             | EC               | CORP              | US        |      1618 | NS      | $1262347.42   | 2.39%             |  |  |  | No            |                  1 | On Loan: No      |
| Abbott Laboratories            | Abbott Laboratories                      | CUSIP: 002824100<br>LEI: HQD377W2YR662HK5JX27 | Long             | EC               | CORP              | US        |     15393 | NS      | $1984157.70   | 3.76%             |  |  |  | No            |                  1 | On Loan: No      |
| Amgen Inc                      | Amgen Inc                                | CUSIP: 031162100<br>LEI: 62QBXGPJ34PQ72Z12S66 | Long             | EC               | CORP              | US        |      3239 | NS      | $1118944.94   | 2.12%             |  |  |  | No            |                  1 | On Loan: No      |
| Edwards Lifesciences Corp      | Edwards Lifesciences Corp                | CUSIP: 28176E108<br>LEI: YA13X31F3V31L8TMPR58 | Long             | EC               | CORP              | US        |      9702 | NS      | $840872.34    | 1.59%             |  |  |  | No            |                  1 | On Loan: No      |
| Ionis Pharmaceuticals Inc      | Ionis Pharmaceuticals Inc                | CUSIP: 462222100<br>LEI: 549300SI4ZGLG0BLUZ92 | Long             | EC               | CORP              | US        |     11318 | NS      | $936338.14    | 1.77%             |  |  |  | No            |                  1 | On Loan: No      |
| Chugai Pharmaceutical Co Ltd   | Chugai Pharmaceutical Co Ltd             | CUSIP: N/A<br>LEI: 529900T9LAII161DCN95       | Long             | EC               | CORP              | JP        |     16311 | NS      | $874417.04    | 1.66%             |  |  |  | No            |                  1 | On Loan: No      |
| Neurocrine Biosciences Inc     | Neurocrine Biosciences Inc               | CUSIP: 64125C109<br>LEI: 549300FECER0XBN49756 | Long             | EC               | CORP              | US        |      3372 | NS      | $513083.52    | 0.97%             |  |  |  | No            |                  1 | On Loan: No      |
| Novartis AG                    | Novartis AG                              | CUSIP: N/A<br>LEI: 5493007HIVTX6SY6XD66       | Long             | EC               | CORP              | CH        |     11319 | NS      | $1472555.25   | 2.79%             |  |  |  | No            |                  1 | On Loan: No      |
| UnitedHealth Group Inc         | UnitedHealth Group Inc                   | CUSIP: 91324P102<br>LEI: 549300GHBMY8T5GXDE41 | Long             | EC               | CORP              | US        |      6577 | NS      | $2168897.29   | 4.11%             |  |  |  | No            |                  1 | On Loan: No      |
| Alnylam Pharmaceuticals Inc    | Alnylam Pharmaceuticals Inc              | CUSIP: 02043Q107<br>LEI: 529900S3ZI14OWRJII50 | Long             | EC               | CORP              | US        |      2019 | NS      | $911033.37    | 1.73%             |  |  |  | No            |                  1 | On Loan: No      |
| Arrowhead Pharmaceuticals Inc  | Arrowhead Pharmaceuticals Inc            | CUSIP: 04280A100<br>LEI: 549300O3CSB8T7OZ3D66 | Long             | EC               | CORP              | US        |     24089 | NS      | $1269490.30   | 2.40%             |  |  |  | No            |                  1 | On Loan: No      |
| Bridgebio Pharma Inc           | Bridgebio Pharma Inc                     | CUSIP: 10806X102<br>LEI: 54930028YG89VTY2J114 | Long             | EC               | CORP              | US        |     15436 | NS      | $1111546.36   | 2.10%             |  |  |  | No            |                  1 | On Loan: No      |
| Crinetics Pharmaceuticals Inc  | Crinetics Pharmaceuticals Inc            | CUSIP: 22663K107<br>LEI: 549300Q1CNFXK5P31D28 | Long             | EC               | CORP              | US        |     20493 | NS      | $933661.08    | 1.77%             |  |  |  | No            |                  1 | On Loan: No      |
| McKesson Corp                  | McKesson Corp                            | CUSIP: 58155Q103<br>LEI: 549300WZWOM80UCFSF54 | Long             | EC               | CORP              | US        |      1168 | NS      | $1029148.16   | 1.95%             |  |  |  | No            |                  1 | On Loan: No      |
| Merck & Co Inc                 | Merck & Co Inc                           | CUSIP: 58933Y105<br>LEI: 4YV9Y5M8S0BRK1RP0397 | Long             | EC               | CORP              | US        |     12963 | NS      | $1358911.29   | 2.57%             |  |  |  | No            |                  1 | On Loan: No      |
| Medtronic PLC                  | Medtronic PLC                            | CUSIP: N/A<br>LEI: 549300GX3ZBSQWUXY261       | Long             | EC               | CORP              | IE        |     15434 | NS      | $1625663.22   | 3.08%             |  |  |  | No            |                  1 | On Loan: No      |
| Ascendis Pharma A/S            | Ascendis Pharma A/S                      | CUSIP: 04351P101<br>LEI: 549300B66JN3W3J8GH73 | Long             | EC               | CORP              | DK        |      2569 | NS      | $545475.77    | 1.03%             |  |  |  | No            |                  1 | On Loan: No      |
| AstraZeneca PLC                | AstraZeneca PLC                          | CUSIP: N/A<br>LEI: PY6ZZQWO2IZFZC3IOL08       | Long             | EC               | CORP              | GB        |     12208 | NS      | $2258155.19   | 4.28%             |  |  |  | No            |                  1 | On Loan: No      |
| Cytokinetics Inc               | Cytokinetics Inc                         | CUSIP: 23282W605<br>LEI: 549300BE5DY1HW7IHA64 | Long             | EC               | CORP              | US        |     14950 | NS      | $1018543.50   | 1.93%             |  |  |  | No            |                  1 | On Loan: No      |
| Insulet Corp                   | Insulet Corp                             | CUSIP: 45784P101<br>LEI: 549300TZTYD2PYN92D43 | Long             | EC               | CORP              | US        |      2246 | NS      | $734868.74    | 1.39%             |  |  |  | No            |                  1 | On Loan: No      |
| Mineralys Therapeutics Inc     | Mineralys Therapeutics Inc               | CUSIP: 603170101<br>LEI: N/A                  | Long             | EC               | CORP              | US        |      6135 | NS      | $264541.20    | 0.50%             |  |  |  | No            |                  1 | On Loan: No      |
| Roche Holding AG               | Roche Holding AG                         | CUSIP: 771195104<br>LEI: 549300U41AUUVOAAOB37 | Long             | EC               | CORP              | CH        |     48754 | NS      | $2331903.82   | 4.42%             |  |  |  | No            |                  1 | On Loan: No      |
| Viking Therapeutics Inc        | Viking Therapeutics Inc                  | CUSIP: 92686J106<br>LEI: 529900IVC72YPFA25M37 | Long             | EC               | CORP              | US        |      9221 | NS      | $339425.01    | 0.64%             |  |  |  | No            |                  1 | On Loan: No      |
| Intellia Therapeutics Inc      | Intellia Therapeutics Inc                | CUSIP: 45826J105<br>LEI: 5493002T5BCPE5DZC723 | Long             | EC               | CORP              | US        |     13524 | NS      | $121580.76    | 0.23%             |  |  |  | No            |                  1 | On Loan: No      |
| Eli Lilly & Co                 | Eli Lilly & Co                           | CUSIP: 532457108<br>LEI: FRDRIPF3EKNDJ2CQJL29 | Long             | EC               | CORP              | US        |      5210 | NS      | $5603198.70   | 10.61%            |  |  |  | No            |                  1 | On Loan: No      |
| Scholar Rock Holding Corp      | Scholar Rock Holding Corp                | CUSIP: 80706P103<br>LEI: 549300Z1FLPGL4OWJ459 | Long             | EC               | CORP              | US        |     12243 | NS      | $539426.58    | 1.02%             |  |  |  | No            |                  1 | On Loan: No      |
| Zealand Pharma A/S             | Zealand Pharma A/S                       | CUSIP: N/A<br>LEI: 549300ITBB1ULBL4CZ12       | Long             | EC               | CORP              | DK        |      5153 | NS      | $413440.93    | 0.78%             |  |  |  | No            |                  1 | On Loan: No      |
| Novo Nordisk A/S               | Novo Nordisk A/S                         | CUSIP: N/A<br>LEI: 549300DAQ1CVT6CXN342       | Long             | EC               | CORP              | DK        |     25819 | NS      | $1271644.67   | 2.41%             |  |  |  | No            |                  1 | On Loan: No      |

### Signature

**Date Signed:** 2026-01-21

**Name of Applicant:** Tema ETF Trust

**Signature:** /s/ Josh Hunter

**Name of Signer:** Josh Hunter

**Title:** Treasurer